SEC EDGARAUG 62 min read$ILMN

Meister Keith A. sold $148.2M of ILMN (indirect holdings)

Meister Keith A. sold 741,127 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $199.91 ($196.74–$203.28, $148.16M total) across 14 trades over 2026-08-04 to 2026-08-05.

Original reporting

SEC EDGAR · Meister Keith A.

Published Aug 6, 2026, 4:00 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Aug 7, 2026, 7:42 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ILMN

Neutral

medium confidence

Mentioned

$ILMN

Relevance

8/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNNeutralLow

Why it matters

A director’s large open-market sale can influence short-term sentiment and options positioning, but the filing does not include any new company-specific performance, guidance, or regulatory developments.

Market read

Traders may monitor for follow-on selling or interpret the transaction as a sentiment signal, but there is no new fundamental catalyst in the text.

What to watch

Indirect holdings and multi-trade execution can reflect pre-planned personal tax or estate liquidity needs rather than a view on ILMN fundamentals.

Relevance 8/10Novelty 5/10Timing: filed Aug 6, covering sales on Aug 4-5

Background

This is an SEC Form 4 insider transaction disclosure for Illumina, Inc. (ILMN).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNNeutralMedium confidence

Context

Illumina director Keith A. Meister sold $148.2M of ILMN via 14 open-market trades at $196.74 to $203.28, indirect holdings.

Expected impact

Likely limited, short-lived negative drift around insider-selling headlines; no direct guidance or business update is provided.

Evidence & confidence

The filing is a Form 4 insider transaction with no 10b5-1 plan and a sizable notional, which can affect sentiment. However, the article contains no new operational, financial, or regulatory facts that would reprice fundamentals.

Market effects

Sector

Could marginally affect sentiment toward genomics tools/diagnostics peers if traders extrapolate insider risk, but no sector-wide catalyst is disclosed.

Regional

Primarily US large-cap sentiment; no cross-region linkage is provided.

Global

No global macro or international transaction details are included.

Counterpoint

What could challenge this read

The sale may be routine liquidity or diversification, and the absence of a stated 10b5-1 plan does not necessarily imply negative company outlook.

Key entities

issuer
Illumina, Inc.
Subject of the Form 4 insider sale; director Keith A. Meister reduced indirect holdings.
insider
Meister Keith A.
Director who sold 741,127 shares across 14 trades for about $148.16M.

Read at source ← All news

OCT 26

$MRNAMed

Moderna’s Rally May Have Run Out of Steam. Here’s What to Watch Next

Moderna (MRNA) shares fell 20% after leaked trial data for its melanoma vaccine, despite analysts calling results 'strong.' The drop may signal the end of its 700% year-to-date rally. Merck (MRK), partnering on the vaccine, saw minimal impact. Analysts expect Merck to report strong earnings. BioNTech (BNTX) and Illumina (ILMN) are also mentioned.

aol.com3 min

OCT 13

$ILMNMed

Illumina Launches $1.0 Billion Unsecured Commercial Paper Program; Signs Dealer Agreements

Illumina established a $1.0 billion unsecured commercial paper program for general corporate purposes. The program allows short-term notes with maturities up to 397 days. A national bank will serve as the issuing and paying agent, with three dealers initially participating. No notes were outstanding as of the filing date.

tradingview.com1 min

OCT 5

$ILMNMed

Illumina (ILMN) Shares Skyrocket, What You Need To Know

Illumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.

financialcontent.com2 min

SEP 24

$ILMNHighAI 8/10

Illumina Soars to New High After Index Win

Illumina (ILMN) shares hit a 52-week high after being added to the S&P 500 Equal Weighted Index. The company announced a $300M note offering, strong earnings, and raised full-year guidance. Analysts increased price targets, citing sustainable earnings and clinical sequencing demand. The stock's rise is driven by index inclusion, debt refinancing, and upgraded guidance, with future growth expected from its sequencer business model.

tipranks.com2 min

SEP 23

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

morningstar.com6 min

SEP 18